Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 259

Results For "STI"

7024 News Found

Healthcare Triangle launches Malaysian subsidiary QuantumNexis
Digitisation | June 20, 2025

Healthcare Triangle launches Malaysian subsidiary QuantumNexis

QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines


USFDA concludes inspection of NATCO’s  Pharma Division, Kothur
Drug Approval | June 20, 2025

USFDA concludes inspection of NATCO’s Pharma Division, Kothur

The company received seven observations in the Form-483


Sanner commences manufacturing critical injection-molded components in USA
Packaging | June 20, 2025

Sanner commences manufacturing critical injection-molded components in USA

The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space


UFlex introduces FSSAI compliant single-pellet solution for food packaging
Packaging | June 20, 2025

UFlex introduces FSSAI compliant single-pellet solution for food packaging

UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials


Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025
News | June 16, 2025

Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025

Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies


AstraZeneca collaborates with CSPC Pharmaceuticals focused on AI-enabled research
News | June 16, 2025

AstraZeneca collaborates with CSPC Pharmaceuticals focused on AI-enabled research

The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing


Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
News | June 16, 2025

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression


FDA approves AbbVie’s mavyret as first and only treatment for acute hepatitis C
Drug Approval | June 13, 2025

FDA approves AbbVie’s mavyret as first and only treatment for acute hepatitis C

Now approved for both acute and chronic HCV in adults and children aged 3 and above